Long-term follow-up results from the Phase I clinical trial of zevorcabtagene autoleucel (zevor-cel, an autologous CAR T-cell product targeting BCMA) were recently presented as a poster at the 22nd International
Learn how BCMA CAR-T therapy works to treat multiple myeloma. This easy-to-understand guide explains benefits, side effects, and what patients can expect from this breakthrough immunotherapy.
Multiple myeloma (MM) remains an incurable blood cancer with high relapse and drug resistance rates. Discover how emerging immunotherapies are reshaping treatment and offering new hope for patients.
The China NMPA has approved the New Drug Application (NDA) for Zevor-cel. This autologous CAR-T product targets BCMA and is intended for adult patients with relapsed or refractory multiple myeloma
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.